Annual report pursuant to Section 13 and 15(d)

REVENUES

v3.24.1
REVENUES
 12 Months Ended
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]  
REVENUES

NOTE 11 – REVENUES

 

Disaggregation of Net Revenues

 

The Company’s net product revenues are summarized below:

           
   

Year Ended

December 31,

  
    2023   2022  
Zembrace Symtouch   $ 6,304   $ —  
Tosymra     1,464     —  
Total product revenues   $ 7,768   $ —  

 

All sales are generated in the United States.

 

Gross-to-Net Sales Accruals

 

We record gross-to-net sales accruals for chargebacks, rebates, sales and other discounts, and product returns, which are all customary to the pharmaceutical industry.

 

Our provision for gross-to-net allowances was $2.9 million at December 31, 2023, $0.6 million of which was recorded as a reduction to accounts receivable and $2.3 million recorded as a component of accrued expenses.